Elliott Management GSK Letter July 2021 — playbook

Elliott Management GSK Letter July 2021

elliott-management-gsk-letter-july-2021 · 2021-07

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

Deck intelligence map

4

coverage by narrative range · generated from this deck JSON

Narrative range 10 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem & Complication 5 slides 100% 5/5 slides 100% 5/5 slides · 28 hits

— 0/5 slides

80% 4/5 slides

— 0/5 slides

100% 5/5 slides 100% 5/5 slides Evidence & Proof 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits

— 0/2 slides

50% 1/2 slides

— 0/2 slides

100% 2/2 slides

— 0/2 slides

Impact & Next Steps 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits

— 0/1 slides

100% 1/1 slides

— 0/1 slides

100% 1/1 slides 100% 1/1 slides · 2 hits Solution & Approach 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits

— 0/2 slides

— 0/2 slides

50% 1/2 slides 100% 2/2 slides 100% 2/2 slides · 4 hits

Slide inventory

19

every slide · same image gating as the playbook

01

This is a formal investor letter from Elliott Advisors to GSK.frame_problem

Open slide detail

02

The table shows cumulative total return comparison in percentages across various time horizons (1-10 years) against a peer group of pharmaceutical companies.frame_problem

Open slide detailBeat · Problem & ComplicationLoop · Cost Of Inaction

03

The slide serves as a summary of the investment rationale, referencing detailed appendices for specific business units and valuation.summarize

Open slide detailBeat · Problem & ComplicationLoop · Cost Of Inaction

04

frame_problem

Open slide detailBeat · Problem & ComplicationLoop · Cost Of Inaction

05

Page number 5 indicates this is part of a larger document.analyze_data

Open slide detailBeat · Problem & ComplicationLoop · Cost Of Inaction

06

The slide highlights a 'credibility gap' and proposes leadership changes as a path forward.frame_problem

Open slide detailBeat · Problem & ComplicationLoop · Cost Of Inaction

07

This slide outlines Elliott's strategic recommendations for GSK's governance and performance management.present_solution

Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction

08

Page 8 of an investor presentation, likely from Elliott Management.present_solution

Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction

09

This is a formal letter page rather than a traditional presentation slide, serving as the concluding section of an activist investor proposal.state_next_steps

Open slide detailBeat · Impact & Next StepsLoop · Cost Of Inaction

10

analyze_data

Open slide detailBeat · Evidence & Proof

11

Includes two bar charts: 2021-2026 revenue CAGR and 2027-2030 revenue change with LOE years.compare_peers

Open slide detailBeat · Evidence & Proof

12

The slide uses a table to detail vaccine performance and includes a callout box summarizing key strategic challenges.summarize

Open slide detail

13

Page 13 of a document, likely an investment research report.summarize

Open slide detail

14

The slide is a text-heavy executive summary page from a larger document.summarize

Open slide detail

15

Contains detailed valuation methodology and assumptions for both business units.analyze_data

Open slide detail

16

The slide uses a waterfall chart to bridge the gap between the sum of parts and current market equity value.analyze_data

Open slide detail

17

This is a text-heavy document page rather than a traditional presentation slide, likely from a report or appendix.establish_context

Open slide detail

18

other

Open slide detail

19

Standard legal disclaimer page for an investor presentation.other

Open slide detail